Rapid Sterility Testing Market Size was valued at USD 2.1 billion in 2022. The Rapid Sterility Testing market industry is projected to grow from USD2.2722 billion in 2023 to USD 4.268395385 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.20% during the forecast period (2023 - 2032).
Increased healthcare providers can also provide these patients with better healthcare, and two things are driving fast growth in the lancet, and pen needles are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
New emerging technologies are driving the market growth
Along with the advancements in the pharmaceutical and medical fields, the demand for sterility tests will also rise. The biotechnology industry is flourishing; this factor will also boost the growth of the sterility testing market over the forecast period. Safety concerns regarding biological medicinal products are also on the rise. Such factors will boost the sterility testing market in the forthcoming years. New technological developments in sterility testing have made the process more efficient, which will drive market growth.
The membrane filtration sterility testing method is the choice for filterable pharmaceutical products. According to the USP <71>, products are filtered through a 0.45 or 0.2-micron membrane filter in this sterility testing method. The filters are then rinsed with appropriate USP fluid to remove the inhibitors and transferred into fluid thioglycollate medium (FTM) and soybean casein digest medium (SCDM). Both media are incubated for 14 days and checked every day for the presence of microbial growth. USP<71> Sterility testing suggests the use of fluid thioglycollate medium (FTM) and soybean casein digest medium (SCDM) because of their ability to promote the growth of anaerobic and aerobic microorganisms, respectively. Techniques like these are drivers for market CAGR.
The Pharma market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%. This is accelerated compared to 5.2% for the years before 2017 but is slower than the other two large healthcare segments, medical equipment, and healthcare services. Healthcare as a whole is growing at over 7% year on year. In pharmaceutical and biopharmaceutical industries, sterility testing is carried out at all levels of manufacturing to minimize the risk of product contamination. Subsequently, the growth of this end-use industry in the coming years will considerably boost the overall use of sterility testing. With stringent regulatory controls, process monitoring, and quality control are carried out for the entire production chain of pharmaceutical and biopharmaceutical products.
In this process, sterility testing is carried out for raw materials, bulk lot release, and final product release testing. In recent years, impressive growth was witnessed in the Pharma and biotech sectors by application; thus, the pharmaceutical and biological manufacturing market has acquired a good market share and is driving the Rapid Sterility Testing market revenue.
Based on Product, the Rapid Sterility Testing market segmentation includes Kits & Reagents, Instruments, and Services. The kits & reagents segment dominated the market; the large share of this segment can primarily be attributed to ease of use, recurring purchase, and growing preference associated with kits & reagents.
Based on Technology, the Rapid Sterility Testing market segmentation includes membrane filtration and ATP bioluminescence. The membrane filtration segment dominated the market. This is due to the growing demand for liquid formulations and the suitability of such tests with samples containing preservatives and bacteriostatic & fungistatic compounds.
Figure 1 Rapid Sterility Testing Market, by Technology, 2022 & 2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on application, the Rapid Sterility Testing market segmentation includes pharmaceutical and biological manufacturing, medical devices. The pharmaceutical and biological manufacturing segment dominated the market. This is because the growing demand for the dosage mentioned above forms ly is one of the major factors supporting the market's growth. Furthermore, the rising number of recalls of these dosage forms due to the lack of sterility further supports the demand for sterility testing of pharmaceuticals.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American rapid sterility testing market area will dominate this market. Many major market players in this Region are expected to contribute significantly to the market growth. In addition, the growing number of established health clubs and fitness facilities will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Rapid Sterility Testing Market Share By Region 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Rapid Sterility Testing market accounts for the second-largest market share dueincreasing harmonization of the regulatory standards with the ICH standards in developing nations. Moreover, many emerging economies in the Region are undertaking various initiatives to boost the domestic pharmaceutical market and are encouraging multinational companies to set up operations in the Region. Further, the German Rapid Sterility Testing market held the largest market share, and the UK Rapid Sterility Testing market was the fastest-growing market in the European Region.
The Asia-Pacific Rapid Sterility Testing Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to expanding awareness of a healthy lifestyle and nutrition and rising per capita disposable income. Moreover, China’s Rapid Sterility Testing market held the largest market share, and the Indian Rapid Sterility Testing market was the fastest-growing market in the Asia-Pacific region.
Rapid sterility testing Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Rapid Sterility Testing market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The rapid sterility testing industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Rapid Sterility Testing industry to benefit clients and increase the market sector. The Rapid Sterility Testing industry has offered some of the most significant medical advantages in recent years. Major players in the Rapid Sterility Testing market, including Terumo Corporation - Japan Beacon Dickinson - USA Sanofi - USA F. Hoffmann-LaRoche - Switzerland Bayer A.G. - Germany Novo Nordisk A.S. - USA Eli Lily and Company - USA Owen Mumford LTD - USA Medtronic - USA Greiner Bio-one - USA Abbott laboratories - USA HTL., and others, are attempting to increase market demand by investing in research and development operations.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and present in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany.Merck KGaA (Switzerland) invested USD 306.5 million in expanding its biosafety testing capacity at Rockville, Maryland, US. This site will provide biosafety testing and analytical development services in the US.
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in various preclinical and clinical laboratory, gene therapy, and cell therapy services for the Pharmaceutical, Medical Device, and Biotechnology industries.Charles River Laboratories, Inc. (US) opened a new High Quality (HQ) Plasmid DNA Centre of Excellence facility at Bruntwood SciTech's Alderley Park in Cheshire, UK. The 16,000 sq. ft facility will provide plasmid DNA manufacturing services.
Key Companies in the rapid sterility testing market include
Rapid sterility testing Industry Developments
November 2022 Merck KGaA (Switzerland) invested USD 306.5 million in expanding its biosafety testing capacity at Rockville, Maryland, US. This site will provide biosafety testing and analytical development services in the US.
September 2022 Merck KGaA (Switzerland) opened its viral clearance (VC) laboratory as the first phase of the China Biologics Testing Center. This site will operate in China and will conduct viral clearance studies locally across preclinical development to commercialization.
June 2022 Charles River Laboratories, Inc. (US) opened a new High Quality (HQ) Plasmid DNA Centre of Excellence facility at Bruntwood SciTech's Alderley Park in Cheshire, UK. The 16,000 sq. ft facility will provide plasmid DNA manufacturing services.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 2.1billion |
| Market Size 2023 | USD 2.2722billion |
| Market Size2032 | USD 4.268395 billion |
| Compound Annual Growth Rate (CAGR) | 8.20%(2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, Application, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Terumo Corporation - Japan Beacon Dickinson - USA Sanofi - USA F. Hoffmann-LaRoche - Switzerland Bayer A.G. - Germany Novo Nordisk A.S. - USA Eli Lily and Company - USA Owen Mumford LTD - USA Medtronic - USA Greiner Bio-one - USA Abbott laboratories - USA HTL |
| Key Market Opportunities | Healthcare providers are also able to provide these patients with better healthcare. |
| Key Market Dynamics | Two things are driving fast growth in the lancet and pen needles market. |
Rapid Sterility Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The Rapid Sterility Testing market size was valued at USD 2.1 Billion in 2022.
The market is projected to grow at a CAGR of 8.20% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in the market areTerumo Corporation - Japan Beacon Dickinson - USA Sanofi - USA F. Hoffmann-LaRoche - Switzerland Bayer A.G. - Germany Novo Nordisk A.S. - USA Eli Lily and Company - USA Owen Mumford LTD - USA Medtronic - USA Greiner Bio-one - USA Abbott laboratories - USA HTL.
The Kits & Reagents Rapid Sterility Testing category dominated the market in 2022.
Membrane Filtration had the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
